Clinical Trials Logo

Clinical Trial Summary

Phase II clinical study will explore dose and safety, immunogenicity in 4 age groups, including 18-59 years old group, 6-17 years old group, 3-5 years old group, 6-35 months old group, with a total of 1716 subjects.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04941261
Study type Interventional
Source National Vaccine and Serum Institute, China
Contact Xia shengli, bachelor
Phone (+86)13592610137
Status Recruiting
Phase Phase 2
Start date June 30, 2021
Completion date March 30, 2024

See also
  Status Clinical Trial Phase
Terminated NCT02371538 - Human Breastmilk in Young Children With Norovirus Infection of the Gut N/A
Completed NCT04188691 - A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine Phase 1
Recruiting NCT05212168 - Norovirus Challenge Study Phase 1/Phase 2
Completed NCT05213728 - A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers Phase 1
Recruiting NCT05626803 - A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers Phase 2
Completed NCT01435811 - Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1) Phase 1
Completed NCT04875676 - Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines Phase 1/Phase 2
Completed NCT04854746 - Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine Phase 1